Case Control Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Apr 14, 2016; 22(14): 3777-3784
Published online Apr 14, 2016. doi: 10.3748/wjg.v22.i14.3777
Figure 1
Figure 1 Area under curve for different P-values thresholds and corresponding numbers of included single nucleotide polymorphisms. The most optimal AUC was achieved with GRS of 33 risk alleles (AUC of 0.78) at P-value threshold of 0.256 (marked with *). Adding 41 SNPs to GRS did not improve GRS significantly, however it presented needless background noise. AUC: Area under curve; GRS: Genetic risk scores; SNPs: Single nucleotide polymorphisms.
Figure 2
Figure 2 Distribution of Genetic risk scores in Crohn’s disease and controls. GRS is normally distributed (Shapiro-Wilk, P > 0.05) in CD cases and controls. Cases have significantly higher GRS (5.32 ± 0.47) than controls (4.78 ± 0.53); P < 10-4. CD: Crohn’s disease; GRS: Genetic risk scores.
Figure 3
Figure 3 Flow diagram for sensitivity (75%) and specificity (72. 7%) in targeted population (Crohn’s disease prevalence 10%). If we test 100 subjects and set the cut-off at 5.05, 32 of them will test positive (above cut-off), with post-test probability of disease approximately 24% (8/33).
Figure 4
Figure 4 Flow diagram for sensitivity (35. 6%) and specificity (93.3%) in targeted population (Crohn’s disease prevalence 10%). If we test 100 subjects and set the cut-off at 5.54, 10 of them will test positive (above cut-off), with post-test probability of disease approximately 40% (4/10).